Harnessing Arsenic Derivatives and Natural Agents for Enhanced Glioblastoma Therapy
Glioblastoma (GBM) is the most common and lethal intracranial tumor in adults. Despite advances in the understanding of the molecular events responsible for disease development and progression, survival rates and mortality statistics for GBM patients have been virtually unchanged for decades and che...
Saved in:
Main Authors: | Bo Yuan, Hidetomo Kikuchi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-12-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/13/24/2138 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH SINGLE-AGENT ARSENIC TRIOXIDE
by: Biju George, et al.
Published: (2011-01-01) -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH SINGLE-AGENT ARSENIC TRIOXIDE
by: Vikram Mathews, et al.
Published: (2011-11-01) -
Study on the leaching behavior of cemented paste backfill containing arsenic trioxide roaster waste
by: Amirhossein Mohammadi, et al.
Published: (2024-12-01) -
Carboplatin combined with arsenic trioxide versus carboplatin combined with docetaxel treatment for LACC: A randomized, open-label, phase II clinical study
by: Li Sijin, et al.
Published: (2024-12-01) -
Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All Trans Retinoic Acid: A Monocentric Experience.
by: Francesco Autore, et al.
Published: (2023-01-01)